GB1106728A - Diuretic and saliuretic sustained-release compositions - Google Patents
Diuretic and saliuretic sustained-release compositionsInfo
- Publication number
- GB1106728A GB1106728A GB2191566A GB2191566A GB1106728A GB 1106728 A GB1106728 A GB 1106728A GB 2191566 A GB2191566 A GB 2191566A GB 2191566 A GB2191566 A GB 2191566A GB 1106728 A GB1106728 A GB 1106728A
- Authority
- GB
- United Kingdom
- Prior art keywords
- benzyl
- ethyl
- methyl
- fatty
- saliuretic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 239000002934 diuretic Substances 0.000 title abstract 3
- 230000001882 diuretic effect Effects 0.000 title abstract 3
- 230000000894 saliuretic effect Effects 0.000 title abstract 3
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- -1 3 - n - butyl Chemical group 0.000 abstract 23
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000001993 wax Substances 0.000 abstract 3
- BBNGVMNBBLPZIR-UHFFFAOYSA-N 4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=CC=C2S(=O)(=O)N=CNC2=C1 BBNGVMNBBLPZIR-UHFFFAOYSA-N 0.000 abstract 2
- 239000000783 alginic acid Substances 0.000 abstract 2
- 235000010443 alginic acid Nutrition 0.000 abstract 2
- 229920000615 alginic acid Polymers 0.000 abstract 2
- 229960001126 alginic acid Drugs 0.000 abstract 2
- 150000004781 alginic acids Chemical class 0.000 abstract 2
- 229920002678 cellulose Polymers 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 abstract 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 abstract 1
- SZLZWPPUNLXJEA-UHFFFAOYSA-N 11,17-dimethoxy-18-[3-(3,4,5-trimethoxy-phenyl)-acryloyloxy]-yohimbane-16-carboxylic acid methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(OC)C1OC(=O)C=CC1=CC(OC)=C(OC)C(OC)=C1 SZLZWPPUNLXJEA-UHFFFAOYSA-N 0.000 abstract 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 abstract 1
- DTBDAFLSBDGPEA-UHFFFAOYSA-N 3-Methylquinoline Natural products C1=CC=CC2=CC(C)=CN=C21 DTBDAFLSBDGPEA-UHFFFAOYSA-N 0.000 abstract 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 abstract 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 abstract 1
- 239000004381 Choline salt Substances 0.000 abstract 1
- CVBMAZKKCSYWQR-BPJCFPRXSA-N Deserpidine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cccc3 CVBMAZKKCSYWQR-BPJCFPRXSA-N 0.000 abstract 1
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical class C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 abstract 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 abstract 1
- 239000004698 Polyethylene Substances 0.000 abstract 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 abstract 1
- HYTGGNIMZXFORS-UHFFFAOYSA-N Protoveratrin A Natural products O1C(C(CCC23C)OC(=O)C(C)(O)CC)(O)C3C(OC(C)=O)C(OC(C)=O)C3C12CC1C(CN2C(CCC(C)C2)C2(C)O)C2C(O)C(OC(=O)C(C)CC)C31O HYTGGNIMZXFORS-UHFFFAOYSA-N 0.000 abstract 1
- 229930189630 Protoveratrine Natural products 0.000 abstract 1
- HYTGGNIMZXFORS-MGYKWWNKSA-N Protoveratrine A Chemical compound O1[C@@]([C@H](CC[C@]23C)OC(=O)[C@@](C)(O)CC)(O)[C@H]3[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]3[C@@]12C[C@H]1[C@H](CN2[C@@H](CC[C@H](C)C2)[C@@]2(C)O)[C@@H]2[C@@H](O)[C@H](OC(=O)[C@H](C)CC)[C@@]31O HYTGGNIMZXFORS-MGYKWWNKSA-N 0.000 abstract 1
- SZLZWPPUNLXJEA-FMCDHCOASA-N Rescinnamine Natural products O=C(O[C@H]1[C@@H](OC)[C@@H](C(=O)OC)[C@@H]2[C@H](C1)CN1[C@@H](c3[nH]c4c(c3CC1)ccc(OC)c4)C2)/C=C/c1cc(OC)c(OC)c(OC)c1 SZLZWPPUNLXJEA-FMCDHCOASA-N 0.000 abstract 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 abstract 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 abstract 1
- ZCDNRPPFBQDQHR-SSYATKPKSA-N Syrosingopine Chemical compound C1=C(OC)C(OC(=O)OCC)=C(OC)C=C1C(=O)O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@H]2C[C@@H]3C(NC=4C5=CC=C(OC)C=4)=C5CCN3C[C@H]2C1 ZCDNRPPFBQDQHR-SSYATKPKSA-N 0.000 abstract 1
- 229920002253 Tannate Polymers 0.000 abstract 1
- 241001250587 Veratrum viride Species 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 1
- 229930013930 alkaloid Natural products 0.000 abstract 1
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 229940125717 barbiturate Drugs 0.000 abstract 1
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 abstract 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000019417 choline salt Nutrition 0.000 abstract 1
- 229960001993 deserpidine Drugs 0.000 abstract 1
- ISMCNVNDWFIXLM-WCGOZPBSSA-N deserpidine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 ISMCNVNDWFIXLM-WCGOZPBSSA-N 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- VQKLRVZQQYVIJW-UHFFFAOYSA-N dihydralazine Chemical compound C1=CC=C2C(NN)=NN=C(NN)C2=C1 VQKLRVZQQYVIJW-UHFFFAOYSA-N 0.000 abstract 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 abstract 1
- 235000019797 dipotassium phosphate Nutrition 0.000 abstract 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 abstract 1
- 235000016693 dipotassium tartrate Nutrition 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 150000002191 fatty alcohols Chemical class 0.000 abstract 1
- 150000002193 fatty amides Chemical class 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 abstract 1
- 229960003602 guanethidine Drugs 0.000 abstract 1
- 150000002357 guanidines Chemical class 0.000 abstract 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 abstract 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 229920000573 polyethylene Polymers 0.000 abstract 1
- AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 abstract 1
- 239000001508 potassium citrate Substances 0.000 abstract 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 abstract 1
- 239000001472 potassium tartrate Substances 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- SFCJOAFKJHVNCF-UHFFFAOYSA-N protoveratrine a and b Chemical class O1C(C(CCC23C)OC(=O)C(C)(O)CC)(O)C3C(OC(C)=O)C(OC(C)=O)C3C12CC1C(CN2C(CCC(C)C2)C2(C)O)C2C(O)C(OC(=O)C(C)CC)C31O.O1C(C(CCC23C)OC(=O)C(C)(O)C(C)O)(O)C3C(OC(C)=O)C(OC(C)=O)C3C12CC1C(CN2C(CCC(C)C2)C2(C)O)C2C(O)C(OC(=O)C(C)CC)C31O SFCJOAFKJHVNCF-UHFFFAOYSA-N 0.000 abstract 1
- 150000003212 purines Chemical class 0.000 abstract 1
- 150000003248 quinolines Chemical class 0.000 abstract 1
- 229960001965 rescinnamine Drugs 0.000 abstract 1
- SMSAPZICLFYVJS-QEGASFHISA-N rescinnamine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)\C=C\C1=CC(OC)=C(OC)C(OC)=C1 SMSAPZICLFYVJS-QEGASFHISA-N 0.000 abstract 1
- 229960003147 reserpine Drugs 0.000 abstract 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 abstract 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 abstract 1
- QORQZMBCPRBCAB-UHFFFAOYSA-N sodium;5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCC(C)C1(CC)C(=O)NC(=O)NC1=O QORQZMBCPRBCAB-UHFFFAOYSA-N 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 abstract 1
- 229960002256 spironolactone Drugs 0.000 abstract 1
- 230000003019 stabilising effect Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 229950006534 syrosingopine Drugs 0.000 abstract 1
- 229960004559 theobromine Drugs 0.000 abstract 1
- 235000015870 tripotassium citrate Nutrition 0.000 abstract 1
- 235000019871 vegetable fat Nutrition 0.000 abstract 1
- 239000000080 wetting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45876365A | 1965-05-25 | 1965-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1106728A true GB1106728A (en) | 1968-03-20 |
Family
ID=23821997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2191566A Expired GB1106728A (en) | 1965-05-25 | 1966-05-17 | Diuretic and saliuretic sustained-release compositions |
Country Status (7)
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001051033A1 (fr) * | 2000-01-14 | 2001-07-19 | Ucb, S.A. | Compositions pharmaceutiques solides pour la liberation controlee de substances actives |
| EA016634B1 (ru) * | 2008-12-29 | 2012-06-29 | Унилевер Н.В. | Замороженные кондитерские изделия и напитки и их применение |
| US11806352B2 (en) | 2010-05-19 | 2023-11-07 | Upfield Europe B.V. | Theobromine for increasing HDL-cholesterol |
-
1966
- 1966-05-17 DE DE19661617372 patent/DE1617372A1/de active Pending
- 1966-05-17 GB GB2191566A patent/GB1106728A/en not_active Expired
- 1966-05-24 DK DK265366A patent/DK113596B/da unknown
- 1966-05-24 FR FR62685A patent/FR5501M/fr not_active Expired
- 1966-05-24 BE BE681486D patent/BE681486A/xx unknown
- 1966-05-24 NL NL6607151A patent/NL6607151A/xx unknown
- 1966-05-24 AT AT490666A patent/AT266324B/de active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001051033A1 (fr) * | 2000-01-14 | 2001-07-19 | Ucb, S.A. | Compositions pharmaceutiques solides pour la liberation controlee de substances actives |
| EP1118321A1 (fr) * | 2000-01-14 | 2001-07-25 | Ucb, S.A. | Compositions pharmaceutiques solides pour la libération contrôlée de substances actives |
| EA016634B1 (ru) * | 2008-12-29 | 2012-06-29 | Унилевер Н.В. | Замороженные кондитерские изделия и напитки и их применение |
| US11806352B2 (en) | 2010-05-19 | 2023-11-07 | Upfield Europe B.V. | Theobromine for increasing HDL-cholesterol |
Also Published As
| Publication number | Publication date |
|---|---|
| DE1617372A1 (de) | 1971-04-01 |
| AT266324B (de) | 1968-11-11 |
| DK113596B (da) | 1969-04-08 |
| BE681486A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1966-11-24 |
| NL6607151A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1966-11-28 |
| FR5501M (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1967-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3456049A (en) | Gradual-release tablet | |
| GB1002211A (en) | Method of preparing sustained release pharmaceutical tablets | |
| NL940014I1 (nl) | Werkwijze voor de bereiding van een geneesmiddel met diuretische en anti-inflammatoire werking aldusverkrijgbaar therapeutisch voorwerp en werkwijze voor het bereiden van daarin te gebruiken 3-sulfamoylpyridine-derivaten | |
| NL187435C (nl) | Esters van gefluoreerde carbonzuren alsmede werkwijze voor het bereiden daarvan. | |
| AR207004A1 (es) | Procedimiento para producir derivados de fenil polienos de acidos carboxilicos farmaceuticamente activos | |
| GB1296505A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPS6339566B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| GB1106728A (en) | Diuretic and saliuretic sustained-release compositions | |
| GB1179938A (en) | Medicinal Sustained-Release Tablets. | |
| AR204843A1 (es) | Nuevos derivados de esteres de acidos o-alquil-s-alquil-o-(pirimidin-4-il)-tionotiolfosforicos de propiedades insecticidas y fitoacaricidas y exentos de accion farmacologica composiciones insecticidas y fitoacaricidas a base de los mismos y procedimiento para la produccion de dichos compuestos | |
| GB760403A (en) | Improvements in or relating to enteric coatings | |
| NL7807594A (nl) | Werkwijze voor het bereiden van gedeeltelijk geneutra- liseerde gemengde esters van melkzuur, citroenzuur en partiele glycerolvetzuuresters. | |
| NL139969B (nl) | Werkwijze voor de bereiding van onverzadigde keto-carbonzuren met diuretische en saluretische werking, alsmede werkwijze voor de bereiding van farmaceutische preparaten die deze verbindingen bevatten en de daarbij verkregen gevormde farmaceutische preparaten. | |
| GB742544A (en) | Enteric products | |
| NL166277B (nl) | Werkwijze voor het bereiden van gemengde esters van hydroxycarbonzuren en partiele vetzuurglyceriden. | |
| Segaloff et al. | Hormonal therapy in cancer of the breast. XIII. The effect of 9 alpha-fluoro-17 alpha-methyl-delta 4-androsten3-one-11 beta-17 beta-diol (fluoxymetherone) therapy on clinical course and hormonal excretion | |
| IE790098L (en) | Solvent vehicle | |
| JPS5616409A (en) | Gamma-oryzanol pharmaceutical preparation | |
| US3071511A (en) | Prednisolone-21-oenanthate octyldodecanol eye lotion | |
| ES369646A1 (es) | Un procedimiento de preparacion de los derivados de acido 5-tiazol carboxilico. | |
| NL7603461A (nl) | D-homosteroiden en werkwijze voor de bereiding daarvan. | |
| JPS5441321A (en) | Remedy for skin diseases and its preparation | |
| KR830001644B1 (ko) | 서방출형 제제의 제조 방법 | |
| NL7802596A (nl) | Werkwijze voor het bereiden van etherderivaten van clavulanzuuresters. | |
| JPS54133549A (en) | Coating composition |